Valuation : Novavax, Inc.

Market Cap 166.93Cr 143.99Cr 135.44Cr 123.39Cr 232.04Cr 16TCr 233.29Cr 1.6TCr 623.23Cr 8.06TCr 626.72Cr 613.13Cr 27TCr P/E 2026 *
-16.2x
P/E 2027 * -45.1x
Enterprise Value 188.82Cr 162.88Cr 153.21Cr 139.58Cr 262.48Cr 18TCr 263.9Cr 1.81TCr 705Cr 9.12TCr 708.94Cr 693.57Cr 30TCr EV / Sales 2026 *
5.06x
EV / Sales 2027 * 7.41x
Free-Float
93.05%
Yield 2026 *
-
Yield 2027 * -
1 day+8.00%
1 week+7.20%
Current month+8.00%
1 month+38.25%
3 months-3.71%
6 months-0.20%
Current year+50.60%
1 week 8.89
Extreme 8.89
10.26
1 month 7.26
Extreme 7.26
10.26
Current year 6.76
Extreme 6.76
11.97
1 year 6.2
Extreme 6.2
11.97
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
277.8
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 23/01/2023
Director of Finance/CFO 60 16/08/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 73 06/08/2010
Director/Board Member 66 01/11/2018
Director/Board Member 60 16/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
20/06/26 Exercice

Director

37,760 0.0230%
18/06/26 Free

Director

35,450 0.0216%
25/04/26 Exercice

Director

19,040 0.0117%
Change 5-day change 1-year change 3-year change Capi.($)
+8.00%+7.20%+35.48%+23.26% 166.93Cr
+0.21%-2.69%+1.19%+17.32% 4.97TCr
+2.09%-0.71%+452.73%+498.77% 4.5TCr
-1.09%-0.41%+35.40%+15.17% 4.25TCr
-0.26%-4.71%+17.19%+71.67% 4.08TCr
-0.48%-0.84%+16.25%+49.80% 3.29TCr
-1.06%+2.87% - - 1.71TCr
-1.81%-5.02%+22.65%+113.24% 1.63TCr
-1.35%-3.40%+10.13%+26.34% 1.44TCr
-2.05%-5.14%+72.89%+34.69% 1.35TCr
Average +0.06%-1.48%+73.77%+94.47% 2.74TCr
Weighted average by Cap. -0.45%-2.21%+96.29%+121.65%

Financials

2026 *2027 *
Net sales 37Cr 32Cr 30Cr 28Cr 52Cr 3.54TCr 52Cr 357.75Cr 139.24Cr 1.8TCr 140.02Cr 136.99Cr 5.97TCr 27Cr 23Cr 22Cr 20Cr 37Cr 2.53TCr 37Cr 255.33Cr 99Cr 1.29TCr 100Cr 98Cr 4.26TCr
Net income -11Cr -9.28Cr -8.73Cr -7.95Cr -15Cr -1.02TCr -15Cr -103.16Cr -40Cr -519.2Cr -40Cr -40Cr -1.72TCr -3.79Cr -3.27Cr -3.08Cr -2.8Cr -5.27Cr -359.95Cr -5.3Cr -36Cr -14Cr -183.1Cr -14Cr -14Cr -607.13Cr
Net Debt 22Cr 19Cr 18Cr 16Cr 30Cr 2.08TCr 31Cr 210.07Cr 82Cr 1.06TCr 82Cr 80Cr 3.51TCr 30Cr 26Cr 25Cr 22Cr 42Cr 2.88TCr 42Cr 290.86Cr 113.21Cr 1.46TCr 113.84Cr 111.37Cr 4.85TCr
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
01/26/01 $10.12 +8.00% 1,00,40,575
31/26/31 $9.370 +1.19% 72,71,750
28/26/28 $9.260 +2.32% 42,11,771
27/26/27 $9.050 -1.74% 34,26,679
26/26/26 $9.210 -2.44% 35,14,522
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
10.12USD
Average target price
14.00USD
Spread / Average Target
+38.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVAX Stock